1
Inpharma 1540 - 3 Jun 2006 Interferon-β-1a and interferon-β-1b have comparable efficacy in MS Interferon-β-1a and interferon-β-1b appear to have similar efficacy in the treatment of patients with relapsing-remitting multiple sclerosis (MS), according to the results of a multicentre, open-label study. 301 such patients were randomised to receive either SC interferon-β-1a 22µg/week (n = 143) or SC interferon-β-1b 250µg every other day, for 24 months. 120 additional patients who declined randomisation received the interferon-β-1b regimen. There was no significant difference in annual relapse rate between the randomised interferon-β-1a and interferon-β-1b groups. However, for interferon-β-1b recipients, the nonrandomised patients had a significantly higher relapse rate in the first year of therapy, compared with the randomised patients. There was no significant difference in mean time to relapse between the randomised interferon-β-1a and interferon- β-1b groups. There was a strong trend towards significance in mean time to relapse difference between the nonrandomised patients and the randomised interferon-β-1b recipients (361 days vs 431 days; p = 0.07). The mean time to sustained progression did not significantly differ between the two randomised treatment groups. However, mean time to progression was significantly shorter in the nonrandomised interferon-β-1b group, compared with the randomised interferon-β-1b recipients (549 days vs 645.6 days). See also Inpharma 1337 p13; 800888287 Koch-Henriksen N, et al. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology 66: 1056-1060, No. 7, 11 Apr 2006 801065181 1 Inpharma 3 Jun 2006 No. 1540 1173-8324/10/1540-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Interferon-β-1a and interferon-β-1b have comparable efficacy in MS

  • View
    213

  • Download
    1

Embed Size (px)

Citation preview

Page 1: Interferon-β-1a and interferon-β-1b have comparable efficacy in MS

Inpharma 1540 - 3 Jun 2006

Interferon-β-1a and interferon-β-1bhave comparable efficacy in MSInterferon-β-1a and interferon-β-1b appear to have

similar efficacy in the treatment of patients withrelapsing-remitting multiple sclerosis (MS), according tothe results of a multicentre, open-label study.

301 such patients were randomised to receive eitherSC interferon-β-1a 22µg/week (n = 143) or SCinterferon-β-1b 250µg every other day, for 24 months.120 additional patients who declined randomisationreceived the interferon-β-1b regimen.

There was no significant difference in annual relapserate between the randomised interferon-β-1a andinterferon-β-1b groups. However, for interferon-β-1brecipients, the nonrandomised patients had asignificantly higher relapse rate in the first year oftherapy, compared with the randomised patients. Therewas no significant difference in mean time to relapsebetween the randomised interferon-β-1a and interferon-β-1b groups. There was a strong trend towardssignificance in mean time to relapse difference betweenthe nonrandomised patients and the randomisedinterferon-β-1b recipients (361 days vs 431 days;p = 0.07).

The mean time to sustained progression did notsignificantly differ between the two randomisedtreatment groups. However, mean time to progressionwas significantly shorter in the nonrandomisedinterferon-β-1b group, compared with the randomisedinterferon-β-1b recipients (549 days vs 645.6 days).

See also Inpharma 1337 p13; 800888287Koch-Henriksen N, et al. A randomized study of two interferon-beta treatments inrelapsing-remitting multiple sclerosis. Neurology 66: 1056-1060, No. 7, 11 Apr2006 801065181

1

Inpharma 3 Jun 2006 No. 15401173-8324/10/1540-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved